A Service of the National Health Information Center, U.S. Department of Health & Human Services
healthfinder® home page
        Help | Advanced Search
 News Library Just For You Health Care Organizations en Español
Health & Human Services Home Page

Home > News


Toxin Combo May Treat Leukemia

  • E-mail this article
  • Subscribe to news
  • TUESDAY, March 16 (HealthDayNews) -- A combination of two natural toxins -- arsenic and bryostatin -- may be a powerful new treatment for certain kinds of leukemia, claims a study in the March 16 issue of the Proceedings of the National Academy of Sciences.

    Researchers at Johns Hopkins Kimmel Cancer Center found that arsenic, long used to treat certain leukemias, activates the same cellular self-destruct mechanism as bryostatin, a toxin that's found in coral-like aquatic organism called a bryozoan that attaches to piers, boat hulls, and rocky surfaces.

    Arsenic is known to be effective against treatment-resistant acute promyelocytic leukemia (APL). It's a cancer of the blood and bone marrow characterized by unhealthy white blood cells. APL is a subtype of acute myeloid leukemia, the most common form of adult leukemia.

    Until now, scientists didn't fully understand how arsenic actually kills cancer cells. The Johns Hopkins scientists used molecular studies to discover that arsenic activates NADPH oxidase, an oxygen-producing enzyme complex.

    "When normal white blood cells engulf invading bacteria, NADPH oxidase produces a big burst of bad oxygen species which they dump into bacteria to kill it and, in the process, kill themselves," Dr. Chi V. Dang, vice dean for research and professor of medicine, cell biology, pathology, and oncology, says in a prepared statement.

    "We found that in APL, arsenic triggers activation of NADPH oxidase and uses this natural bacteria-killing mechanism against the leukemia cells -- in essence, a self-destruct switch," Dang says.

    But he and his colleagues found arsenic alone didn't pack quite enough punch; it left much of the NADPH dormant.

    The Johns Hopkins scientists turned to bryostatin. Previous molecular studies found bryostatin also activates NADPH.

    "So, we used bryostatin to wake up the rest of (the NADPH)," Dang says.

    This combination requires further study in cells and animals before clinical trials can be conducted on people with APL.

    More information

    The American Cancer Society has more about leukemia.

    (SOURCE: Johns Hopkins Medical Institutions, news release, March 15, 2004)

    Copyright © 2004 ScoutNews, LLC. All rights reserved.

    HealthDayNews articles are derived from various sources and do not reflect federal policy. healthfinder® does not endorse opinions, products, or services that may appear in news stories. For more information on health topics in the news, visit the healthfinder® health library.
    About Us  Accessibility  Disclaimer  Freedom of Information Act  Privacy  Contact Us
    Office of Disease Prevention and Health Promotion, U.S. Department of Health & Human Services